<DOC>
	<DOC>NCT00829816</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.</brief_summary>
	<brief_title>Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Alzheimer's disease On Memantine Caregiver who is willing to accompany the patient to all clinic visits Unstable medical illnesses or significant hepatic or renal disease Other primary psychiatric or neurological disorders</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Alzheimers disease</keyword>
	<keyword>donepezil</keyword>
	<keyword>memantine</keyword>
</DOC>